Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTS87KH)

• DTT Name: Microtubule-associated protein tau (MAPT) DTT Info
• Gene Name: MAPT

Molecule-Related Drug & Molecule List

17 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[1]
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[2]
TRx0237	DM0QNF4	Alzheimer disease	8A20	Phase 3	[3]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[4]
Bepranemab	DMRQIJO	Alzheimer disease	8A20	Phase 2	[5]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[6]
JNJ-63733657	DMMKWGJ	Alzheimer disease	8A20	Phase 2	[7]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[8]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[6]
Semorinemab	DMA17VD	Alzheimer disease	8A20	Phase 2	[9]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[1]
APNmAb005	DMDVRPZ	Alzheimer disease	8A20	Phase 1	[10]
BEY2153	DMCB2Z0	Alzheimer disease	8A20	Phase 1	[11]
Lu AF87908	DMFSPAT	Alzheimer disease	8A20	Phase 1	[12]
LY3303560	DMG6HLE	Alzheimer disease	8A20	Phase 1	[13]
PRX-005	DMAL2OW	Alzheimer disease	8A20	Phase 1	[14]
PTI-80	DM0A6N9	Alzheimer disease	8A20	Phase 1	[15]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AL-408	DM7K360	Central nervous system disease	8A04-8D87	Investigative	[1]
BLV-0703	DMBRZ4P	Central nervous system disease	8A04-8D87	Investigative	[1]
NI-105	DMPK2JO	Neurodegenerative disorder	8A20-8A23	Investigative	[1]

References

• [1] Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
• [2] Clinical pipeline report, company report or official report of TauRx.
• [3] Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
• [4] Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
• [5] Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.
• [8] PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
• [9] Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
• [10] Clinical pipeline report, company report or official report of Aprinoia Therapeutics
• [11] Clinical pipeline report, company report or official report of BeyondBio
• [12] Clinical pipeline report, company report or official report of Lundbeck
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of Prothena
• [15] Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.